A recent clinical trial specifically excluding patients with EGFR‐mutations showed a longer overall survival (5.9 vs. 7.5 months for placebo treated vs. ruxolitinib treated, hazard ratio = 0.877) when combining ruxolitinib and chemotherapy in non‐small cell lung cancer patients (NCT02119650). The gene discussed is EGFR; the disease is lung cancer.